Log in

Aravive Stock Forecast, Price & News

+0.42 (+7.23 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $6.23
50-Day Range
MA: $5.81
52-Week Range
Now: $6.23
Volume246,593 shs
Average Volume198,080 shs
Market Capitalization$100.17 million
P/E RatioN/A
Dividend YieldN/A
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARAV



Sales & Book Value

Annual Sales$4.75 million
Book Value$4.71 per share


Net Income$-18,220,000.00


Market Cap$100.17 million
Next Earnings Date11/5/2020 (Estimated)
+0.42 (+7.23 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock price been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARAV shares have increased by 24.8% and is now trading at $6.23.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Aravive?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aravive

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aravive

How were Aravive's earnings last quarter?

Aravive Inc (NASDAQ:ARAV) released its earnings results on Monday, August, 3rd. The company reported ($0.32) EPS for the quarter, beating the Zacks' consensus estimate of ($0.46) by $0.14.
View Aravive's earnings history

What price target have analysts set for ARAV?

7 equities research analysts have issued 1 year price targets for Aravive's stock. Their forecasts range from $24.00 to $31.00. On average, they anticipate Aravive's share price to reach $28.40 in the next twelve months. This suggests a possible upside of 355.9% from the stock's current price.
View analysts' price targets for Aravive

Are investors shorting Aravive?

Aravive saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,160,000 shares, an increase of 10.5% from the August 15th total of 1,050,000 shares. Based on an average daily volume of 259,700 shares, the days-to-cover ratio is currently 4.5 days. Currently, 12.0% of the company's shares are sold short.
View Aravive's Short Interest

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Vinay Shah, Chief Financial Officer
  • Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by many different retail and institutional investors. Top institutional investors include Artal Group S.A. (8.62%), FMR LLC (4.84%), Two Sigma Advisers LP (0.96%), Nuveen Asset Management LLC (0.29%), Bank of New York Mellon Corp (0.28%) and Charles Schwab Investment Management Inc. (0.17%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju.
View institutional ownership trends for Aravive

Which institutional investors are selling Aravive stock?

ARAV stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Bank of Montreal Can, and Two Sigma Advisers LP.
View insider buying and selling activity for Aravive

Which institutional investors are buying Aravive stock?

ARAV stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., California Public Employees Retirement System, Goldman Sachs Group Inc., Alps Advisors Inc., and Bank of America Corp DE.
View insider buying and selling activity for Aravive

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $6.23.

How big of a company is Aravive?

Aravive has a market capitalization of $100.17 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.